<doc>
  <docmeta id="113s2862is">
    <bill congress="113" type="s" number="2862" version="is"/>
    <revision size="10512" annotations="0" status="complete" id="6" commit-time="2014-10-10T19:42:22Z" committer="mbohmer" doc="113s2862is/6.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" public-private="public">
  <metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 S2862 IS: Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. Senate</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-09-18</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code>
    <congress>113th CONGRESS</congress>
    <session>2d Session</session>
    <legis-num>S. 2862</legis-num>
    <current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
    <action>
      <action-date date="20140918">September 18, 2014</action-date>
      <action-desc>
        <sponsor name-id="S118">Mr. Hatch</sponsor> (for himself and <cosponsor name-id="S316">Mr. Whitehouse</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name>
      </action-desc>
    </action>
    <legis-type>A BILL</legis-type>
    <official-title>To amend the Controlled Substances Act with respect to drug scheduling recommendations by the
			 Secretary of Health and Human Services, and with respect to registration
			 of manufacturers and distributors seeking to conduct clinical testing, and
			 for other purposes. </official-title>
  </form>
  <legis-body id="H3D7856030F154CAB9CA7B3EE1120FC3D" style="OLC">
    <section id="H50C178AFA00F4508B6D6A6560D7B53ED" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014" proposed="true">Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014</cato:entity-ref>
          </short-title>
        </quote>.</text>
    </section>
    <section id="H99F61C2A5E3C4A798F9F2149DD18DFE0">
      <enum>2.</enum>
      <header>Scheduling of substances included in new FDA-approved drugs</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:201">Section 201 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/811">
          <cato:entity-ref entity-type="uscode" value="usc/21/811">21 U.S.C. 811</cato:entity-ref>
        </external-xref>)</cato:entity> is amended by inserting after
			 subsection (h) the following:</text>
      <quoted-block id="HF92623B6E0604C849F1CB660CB9CF7B9" style="OLC">
        <subsection id="H956A198CA01D4E9699386C70F5CD2DFE">
          <enum>(i)</enum>
          <text display-inline="yes-display-inline">Within 45 days of receiving a recommendation from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to add a drug or substance that has
			 never been marketed in the United States to a schedule under this title,
			 the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> shall, without regard to the findings required by
			 subsection (a) of this section or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:202/ss:b">section 202(b)</cato:entity-ref>, issue an interim final
			 rule, under the exception for good cause described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/553/b//B">subparagraph (B) of
			 <external-xref legal-doc="usc" parsable-cite="usc/5/553">section 553(b)</external-xref> of title 5, United States Code</cato:entity-ref>, placing the drug or
			 substance into the schedule recommended by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>. The interim
			 final rule shall be made immediately effective under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/553/d/3">section 553(d)(3) of
			 title 5, United States Code</cato:entity-ref>.</text>
        </subsection>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
    </section>
    <section id="H3DB6FFA0B1A74E0EB1E5F0DD55D30F01">
      <enum>3.</enum>
      <header>Enhancing new drug development</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:302">Section 302 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/822">
          <cato:entity-ref entity-type="uscode" value="usc/21/822">21 U.S.C. 822</cato:entity-ref>
        </external-xref>)</cato:entity> is amended by inserting after
			 subsection (g) the following:</text>
      <quoted-block id="HC162F4D7FAF94B0AA24C8186367E9B1A" style="OLC">
        <subsection id="HF2A73ADF44F54B218F20AFB7008F5C92">
          <enum>(h)</enum>
          <paragraph commented="no" display-inline="yes-display-inline" id="HDD63E7052F8E473FA3B96EE446648EDB">
            <enum>(1)</enum>
            <text>A person who submits an application for registration to manufacture or distribute a controlled
			 substance in accordance with this section may indicate on the registration
			 application that the substance will be used only in connection with
			 clinical trials of a drug in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:i">section 505(i) of the Federal
			 Food, Drug, and Cosmetic Act</cato:entity-ref>.</text>
          </paragraph>
          <paragraph id="H651AEA7933CD43319C7BA55231DE9DD9" indent="up1">
            <enum>(2)</enum>
            <text>When an application for registration to manufacture or distribute a controlled substance includes
			 an indication that the controlled substance will be used only in
			 connection with clinical trials of a drug in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:i">section
			 505(i) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref>
			 shall—</text>
            <subparagraph id="H3942D2C99E324569A4794CC20039393A">
              <enum>(A)</enum>
              <text>make a final decision on the application for registration within 180 days; or</text>
            </subparagraph>
            <subparagraph id="HBC6ACE82E98E4FE39214CD01729720E1">
              <enum>(B)</enum>
              <text>provide notice to the applicant in writing of—</text>
              <clause id="H41FD75B83D884EF2A12A07311FF5C866">
                <enum>(i)</enum>
                <text>the outstanding issues that must be resolved in order to reach a final decision on the application;
			 and</text>
              </clause>
              <clause id="H1050D99947004C93B7AE35C5AF3884B1">
                <enum>(ii)</enum>
                <text>the estimated date on which a final decision on the application will be made.</text>
              </clause>
            </subparagraph>
          </paragraph>
        </subsection>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
    </section>
    <section id="HCE607419F1D34D6EB8A11EC312ECD226">
      <enum>4.</enum>
      <header>Registration process under Controlled Substances Act</header>
      <subsection id="H5306A535106842CEA7168B562BABAC6E">
        <enum>(a)</enum>
        <header>Definitions</header>
        <paragraph id="H22FA1DC728154998BCE7EE52F234919D">
          <enum>(1)</enum>
          <header>Factors as may be relevant to and consistent with the public health and safety</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:303">Section 303 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/823">
              <cato:entity-ref entity-type="uscode" value="usc/21/823">21 U.S.C. 823</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by adding at the end the
			 following:</text>
          <quoted-block display-inline="no-display-inline" id="H363843CE43714E49AB156F60AAB21DB1" style="OLC">
            <subsection id="HC569CBA06D4C441EBBFAD425B60CF527">
              <enum>(i)</enum>
              <text display-inline="yes-display-inline">In this section, the phrase <quote>factors as may be relevant to and consistent with the public health and safety</quote> means factors that are relevant to and consistent with the findings contained in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:101">section 101</cato:entity-ref>.</text>
            </subsection>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
        <paragraph id="H900618BBCC944BB8BCC639DC372E5130">
          <enum>(2)</enum>
          <header>Imminent danger to the public health or safety</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:304/ss:d">Section 304(d) of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/824">
              <cato:entity-ref entity-type="uscode" value="usc/21/824/d">21 U.S.C. 824(d)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended—</text>
          <subparagraph id="HEFBB9A0247584D26BEC2EB0DCCD49C04">
            <enum>(A)</enum>
            <text>by striking <quote>(d) The Attorney General
              </quote> and inserting <quote>(d)(1) The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref>
              </quote>; and</text>
          </subparagraph>
          <subparagraph id="H4138CA7EE7C94012821D34183B7874E5">
            <enum>(B)</enum>
            <text>by adding at the end the following:</text>
            <quoted-block display-inline="no-display-inline" id="HDEF025DDA7BA4A52B7C7F6B6761B987D" style="OLC">
              <paragraph id="H7C924D2D4300454084F72F687BDFFECE" indent="up1">
                <enum>(2)</enum>
                <text display-inline="yes-display-inline">In this subsection, the phrase <term>imminent danger to the public health or safety</term> means that, in the absence of an immediate suspension order, controlled substances will continue
			 to be distributed or dispensed by a registrant who knows or should know
			 through fulfilling the obligations of the registrant under this Act, or
			 has reason to
			 believe that—</text>
                <subparagraph id="idB02483A43EBB48CEA74AE9BD4EB5F683">
                  <enum>(A)</enum>
                  <text>the dispensing is outside the usual course of professional practice;</text>
                </subparagraph>
                <subparagraph id="id7F47C60A80FD4934A802C91D108492B8">
                  <enum>(B)</enum>
                  <text>the distribution or dispensing poses a present or foreseeable risk of adverse health consequences
			 or death due to the abuse or misuse of the controlled substances; or</text>
                </subparagraph>
                <subparagraph id="id9F0A2C0302A4474BB99F6A6E5D7F53FE">
                  <enum>(C)</enum>
                  <text>the controlled substances will continue to be diverted outside of legitimate distribution channels.</text>
                </subparagraph>
              </paragraph>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
          </subparagraph>
        </paragraph>
      </subsection>
      <subsection id="H919D5C29D791499D832B0BC019DE76A9">
        <enum>(b)</enum>
        <header>Opportunity To submit corrective action plan prior to revocation or suspension</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:304/ss:c">Subsection (c) of section 304 of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/824">
            <cato:entity-ref entity-type="uscode" value="usc/21/824">21 U.S.C. 824</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text>
        <paragraph id="HF86ED9E88D30482C87DB31431C217892">
          <enum>(1)</enum>
          <text>by striking the last two sentences;</text>
        </paragraph>
        <paragraph id="H01F77CA56680471B96B9E7936C123503">
          <enum>(2)</enum>
          <text>by striking <quote>(c) Before</quote> and inserting <quote>(c)(1) Before</quote>; and</text>
        </paragraph>
        <paragraph id="H96F65A1C309343CEB8A271E50783F677">
          <enum>(3)</enum>
          <text>by adding at the end the following:</text>
          <quoted-block display-inline="no-display-inline" id="H14A81C371A124B00B74C1BB759D2A90F" style="OLC">
            <paragraph id="H818C725CA32941F5AE4C7B4FF743064F" indent="up1">
              <enum>(2)</enum>
              <text>An order to show cause under paragraph (1) shall—</text>
              <subparagraph id="H7DC04F26446D43BBA5C365797A994BA4">
                <enum>(A)</enum>
                <text>contain a statement of the basis for the denial, revocation, or suspension, including specific
			 citations to any laws or regulations alleged to be violated by the
			 applicant or registrant;</text>
              </subparagraph>
              <subparagraph id="H58F9BAD54DF947388CBCFC0074A7E79F">
                <enum>(B)</enum>
                <text>direct the applicant or registrant to appear before the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> at a time and place stated
			 in the order, but not less than 30 days after the date of receipt of
			 the order; and</text>
              </subparagraph>
              <subparagraph id="H81EBEE957CBB4B5193ABFB19D42B4A03">
                <enum>(C)</enum>
                <text>notify the applicant or registrant of the opportunity to submit a corrective action plan on or
			 before the date of appearance.</text>
              </subparagraph>
            </paragraph>
            <paragraph id="HDDAEB68EE86C46EF846AD61851444FFE" indent="up1">
              <enum>(3)</enum>
              <text>Upon review of any corrective action plan submitted by an applicant or registrant pursuant to
			 paragraph (2), the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1500" entity-type="federal-body">Attorney General</cato:entity-ref> shall determine whether denial,
			 revocation or suspension proceedings should be discontinued, or deferred
			 for the purposes of modification, amendment, or clarification to such
			 plan.</text>
            </paragraph>
            <paragraph id="HC341FA78C8EC4E3CBB1E42489F7E23F6" indent="up1">
              <enum>(4)</enum>
              <text>Proceedings to deny, revoke, or suspend shall be conducted pursuant to this section in accordance
			 with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc-chapter/5/5/II">subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/5">chapter 5</external-xref> of title 5, United States Code</cato:entity-ref>. Such
			 proceedings shall be
			 independent of, and not in lieu of, criminal prosecutions or other
			 proceedings under this title or any other law of the United States.</text>
            </paragraph>
            <paragraph id="H36C826AE1CBE4AFE9602499F09552B68" indent="up1">
              <enum>(5)</enum>
              <text>The requirements of this subsection shall not apply to the issuance of an immediate suspension
			 order under subsection (d).</text>
            </paragraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
      </subsection>
    </section>
    <section id="HA72B90AD1F004BD59C5A71765787DF1B">
      <enum>5.</enum>
      <header>Report to Congress on effects of law enforcement activities on patient access to medications</header>
      <subsection id="HFD8E94DA3E174658B6776898F6C155B7">
        <enum>(a)</enum>
        <header>In general</header>
        <text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human
			 Services</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Commissioner of Food and Drugs</cato:entity-ref> and the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7523" entity-type="federal-body">Director of the Centers for Disease Control and Prevention</cato:entity-ref>, and in
			 consultation with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1524" entity-type="federal-body">Administrator of the Drug Enforcement Administration</cato:entity-ref>
			 and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1127">Director of National Drug Control Policy</cato:entity-ref>, shall submit a report to
			 the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="HJU00" entity-type="committee">Committees on the Judiciary of the House of Representatives</cato:entity-ref>, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="HIF00" entity-type="committee">Committee on Energy and Commerce of the House of Representatives</cato:entity-ref>, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="SSJU00" entity-type="committee">Committee on the Judiciary of the Senate</cato:entity-ref>, and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="SSHR00" entity-type="committee">Committee on Health,
			 Education, Labor and Pensions of the Senate</cato:entity-ref> identifying—</text>
        <paragraph id="HD2C44B04DD6A410D90EAD7172EA7BEFB">
          <enum>(1)</enum>
          <text>obstacles to legitimate patient access to controlled substances;</text>
        </paragraph>
        <paragraph id="H2BC13C38B23E48C98ADC53AE2A19F530">
          <enum>(2)</enum>
          <text>issues with diversion of controlled substances; and</text>
        </paragraph>
        <paragraph id="H21717A3FD57A44448BD166B441E02C96">
          <enum>(3)</enum>
          <text>how collaboration between Federal, State, local, and tribal law enforcement agencies and the
			 pharmaceutical industry can benefit patients and prevent diversion and
			 abuse of controlled substances.</text>
        </paragraph>
      </subsection>
      <subsection id="H7DED1A4A89A7442EA504E8EC24DF85E9">
        <enum>(b)</enum>
        <header>Consultation</header>
        <text display-inline="yes-display-inline">The report under subsection (a) shall incorporate feedback and recommendations from the following:</text>
        <paragraph id="H092E27C086584A9FB8D1B652B975F6FD">
          <enum>(1)</enum>
          <text>Patient groups.</text>
        </paragraph>
        <paragraph id="H5CD65F75C12849BDA6D28D3B4B888192">
          <enum>(2)</enum>
          <text>Pharmacies.</text>
        </paragraph>
        <paragraph id="H9469E001598C4B808B8554CF74A3EAE5">
          <enum>(3)</enum>
          <text>Drug manufacturers.</text>
        </paragraph>
        <paragraph id="H4C1B8E43FFE643FE9E5FAFB80C1C3D6B">
          <enum>(4)</enum>
          <text>Common or contract carriers and warehousemen.</text>
        </paragraph>
        <paragraph id="HECACCE814CF34A90AD1D19D19CAA8931">
          <enum>(5)</enum>
          <text>Hospitals, physicians, and other health care providers.</text>
        </paragraph>
        <paragraph id="HA5BEFFAC62054C27B0C0FFC7FA48F57C">
          <enum>(6)</enum>
          <text>State attorneys general.</text>
        </paragraph>
        <paragraph id="H44FB8066A4584465AEAB20596F6A349C">
          <enum>(7)</enum>
          <text display-inline="yes-display-inline">Federal, State, local, and tribal law enforcement agencies.</text>
        </paragraph>
        <paragraph id="HBF1D70DCC8A34E7098D1B9295EF8D2CF">
          <enum>(8)</enum>
          <text>Health insurance providers and entities that provide pharmacy benefit management services on behalf
			 of a health insurance provider.</text>
        </paragraph>
        <paragraph commented="no" display-inline="no-display-inline" id="HF98C2C07D6FB4FB9A1007FC08F5C1729">
          <enum>(9)</enum>
          <text>Wholesale drug distributors.</text>
        </paragraph>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>